Hengrui presents 64 research studies at ESMO 2026 congress
Hengrui has showcased 64 research presentations at the ESMO 2026 congress, highlighting the company's expanded focus on international oncology development.
Chinese pharmaceutical company Hengrui has debuted 64 research projects at the ESMO 2026 congress, signaling a major push into the international oncology market. The presentations cover a wide range of clinical research aimed at identifying new approaches to cancer treatment.
The volume of research presented underscores the company's significant investment in research and development. By scaling its presence at major global medical forums, Hengrui aims to transition from a regional player to a broader competitor in the global oncology sector.
These findings follow years of increased internal R&D spending. The company continues to prioritize clinical trials that focus on addressing gaps in current standard-of-care treatments for solid tumors and other malignancies.